Innate Pharma SA (IPH)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€1.16

Buy

€1.178

arrow-up€0.038 (+3.38%)

Prices updated at 02 Apr 2026, 16:35 CEST

Prices minimum 15 mins delay

Prices in EUR

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in developing immunotherapy drugs for cancer and inflammatory diseases.

FTSE EuroFirst 300

-0.19%

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

-

CEO

Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A.

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

174

Head office

117, Avenue de Luminy

Marseille

France

13009

+33 430303030

investors@innate-pharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Jonathan Elliott Dickinson, B.Sc. ,M.B.A. Member of the Supervisory Board, Member of the Executive Board and Chief Executive Officer	0.09m
Ms. Irina Staatz-Granzer, PhD Chairwoman of the Supervisory Board	0.04m
Dr. Veronique Chabernaud, M.D. Member of the Supervisory Board	0.06m
Ms. Pascale Boissel Vice Chairwoman of the Supervisory Board	0.04m
Ms. Sally Bennett Member of the Supervisory Board	-
Mr. Olivier Martinez Member of the Supervisory Board	-
Mr. Yannis Morel, PhD Member of the Executive Board, Executive Vice President and Chief Operating Officer	0.30m
Professor Jean-Yves Blay, PhD Member of the Supervisory Board	-
Mr. Gilles Brisson Member of the Supervisory Board	0.03m
Ms. Odile Belzunce Vice President, Compliance, IT and Portfolio Management	-
Mr. Eric Vivier, D.V.M.,PhD Senior Vice President and Chief Scientific Officer	-
Ms. Odile Laurent, M.B.A.,PhD Vice President, Human Resources	-
Mr. Frederic Lombard, M.B.A. Chief Financial Officer	-
Ms. Nicola Beltraminelli, PhD Vice President and Chief Development Officer	-
Mr. Henry Wheeler, M.Sc. Vice President, Investor Relations and Communications	-
Ms. Claire de Saint Blanquat Vice President, Legal and Corporate Affairs	-
Dr. Sonia Quaratino, M.D.,PhD Member of the Executive Board, Chief Medical Officer and Executive Vice President	0.35m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Saint Olive Gestion	170,000
Generali Asset Management S.p.A. Società di gestione del risparmio	124,638
Generali France PME ETI	124,638
BSO Euro Santé	100,000
GF Ambition Solidaire	99,951

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.